A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Celiac Disease
Coeliac Disease

Interventions

DRUG: KAN-101
DRUG: Placebo

Sponsor

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

Collaborators

[object Object]